Breast tomosynthesis after screening mammography reduces need for ultrasound, biopsies

Breast tomosynthesis in the diagnostic workup for one- or two-view focal asymmetry detected at screening mammography resulted in less use of ultrasound, fewer biopsies, and higher positive predictive value for cancer than when diagnostic exams involved only 2D mammography, according to a study conducted at the University of Virginia.

"Tomosynthesis has been evaluated in screening populations and been shown to decrease recall rates," said researcher Brandi Nicholson, "but studies in the diagnostic setting are lacking."

Five hundred thirty two patients who were recalled for a focal asymmetric density discovered at screening were analyzed across three categories: women recalled prior to the availability of tomosynthesis in the practice (PT), those who did not have tomosynthesis at after it was available (NT), and those who had diagnostic tomosynthesis (YT). There were 238 patients in the PT group, 145 in the NT group, and 149 in the YT group.

The researchers found that additional full views and ultrasound were performed significantly less frequently in the YT group than in both the PT and NT groups. They also found that the PPV was increased for the YT group compared to both the PT and NT groups.

More information: Dr. Nicholson presented the study on May 5 at the 2014 ARRS Annual Meeting in San Diego, CA.

add to favorites email to friend print save as pdf

Related Stories

Tomosynthesis ups accuracy of digital mammography

Jan 04, 2013

(HealthDay)—Using a combination of tomosynthesis, which produces a three-dimensional reconstruction of the breast, with digital mammography increases radiologists' diagnostic accuracy and significantly ...

Recommended for you

Gene test aids cancer profile

9 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

How a common antacid could lead to cheaper anti-cancer drugs

Nov 26, 2014

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.